Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clenbuterol→

Clenbuterol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
37148-27-9
Molecular formula
C12H18Cl2N2O
Molecular weight
277.19 g/mol
Drug class
Selective beta-2 adrenergic receptor agonistsympathomimetic bronchodilator
Mechanism of action
Stimulates beta-2 adrenergic receptors in bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, which relaxes airway smooth muscle. At higher exposures it can produce systemic beta-adrenergic effects.
Indications / reported uses
  • Bronchodilator use for reversible airway obstruction in jurisdictions where a clenbuterol medicinal product is authorised; not approved for human medical use in some countries, including the United States. It is prohibited in sport under anti-doping rules.

Sources: NLM MeSH — Clenbuterol · Sport Integrity Australia — Clenbuterol · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Selective beta-2 adrenergic receptor agonist; sympathomimetic bronchodilator

Mechanism of action

Stimulates beta-2 adrenergic receptors in bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, which relaxes airway smooth muscle. At higher exposures it can produce systemic beta-adrenergic effects.

General use cases

  • Bronchodilator use for reversible airway obstruction in jurisdictions where a clenbuterol medicinal product is authorised; not approved for human medical use in some countries, including the United States. It is prohibited in sport under anti-doping rules.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Clenbuterol Environmental Risk Assessment (ERA) (the Clenbuterol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.